113 related articles for article (PubMed ID: 20225650)
1. Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.
Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Minowa K; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Tsunoda S; Tsutsumi Y
Pharmazie; 2010 Feb; 65(2):93-6. PubMed ID: 20225650
[TBL] [Abstract][Full Text] [Related]
2. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
[TBL] [Abstract][Full Text] [Related]
3. Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2.
Shibata H; Abe Y; Yoshioka Y; Nomura T; Sato M; Kayamuro H; Kawara T; Arita S; Furuya T; Nagano K; Yoshikawa T; Kamada H; Tsunoda S; Tsutsumi Y
Cytokine; 2010 Apr; 50(1):75-83. PubMed ID: 20045350
[TBL] [Abstract][Full Text] [Related]
4. Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.
Abe Y; Yoshikawa T; Inoue M; Nomura T; Furuya T; Yamashita T; Nagano K; Nabeshi H; Yoshioka Y; Mukai Y; Nakagawa S; Kamada H; Tsutsumi Y; Tsunoda S
Biomaterials; 2011 Aug; 32(23):5498-504. PubMed ID: 21546081
[TBL] [Abstract][Full Text] [Related]
5. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
[TBL] [Abstract][Full Text] [Related]
6. Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.
Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Taniai M; Ohta T; Tsunoda S; Tsutsumi Y
Biochem Biophys Res Commun; 2009 Oct; 388(4):667-71. PubMed ID: 19682974
[TBL] [Abstract][Full Text] [Related]
7. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.
Shibata H; Yoshioka Y; Abe Y; Ohkawa A; Nomura T; Minowa K; Mukai Y; Nakagawa S; Taniai M; Ohta T; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Dec; 30(34):6638-47. PubMed ID: 19765818
[TBL] [Abstract][Full Text] [Related]
8. Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system.
Yoshioka Y; Watanabe H; Morishige T; Yao X; Ikemizu S; Nagao C; Ahmad S; Mizuguchi K; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Biomaterials; 2010 Mar; 31(7):1935-43. PubMed ID: 19853911
[TBL] [Abstract][Full Text] [Related]
9. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity.
Abe Y; Yoshikawa T; Kamada H; Shibata H; Nomura T; Minowa K; Kayamuro H; Katayama K; Miyoshi H; Mukai Y; Yoshioka Y; Nakagawa S; Tsunoda S; Tsutsumi Y
J Immunol Methods; 2008 Jun; 335(1-2):71-8. PubMed ID: 18417150
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and blocked by caspase-8 inhibitors.
Depuydt B; van Loo G; Vandenabeele P; Declercq W
J Cell Sci; 2005 Feb; 118(Pt 3):497-504. PubMed ID: 15657078
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
Nomura T; Abe Y; Kamada H; Shibata H; Kayamuro H; Inoue M; Kawara T; Arita S; Furuya T; Yamashita T; Nagano K; Yoshikawa T; Yoshioka Y; Mukai Y; Nakagawa S; Taniai M; Ohta T; Serada S; Naka T; Tsunoda S; Tsutsumi Y
J Control Release; 2011 Jan; 149(1):8-14. PubMed ID: 20036293
[TBL] [Abstract][Full Text] [Related]
12. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
Qin W; Feng J; Li Y; Lin Z; Shen B
Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-alpha-induced skin inflammation.
Kondo S; Sauder DN
Eur J Immunol; 1997 Jul; 27(7):1713-8. PubMed ID: 9247582
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor (TNF)-induced cutaneous necrosis is mediated by TNF receptor 1.
Amar S; Van Dyke TE; Eugster HP; Schultze N; Koebel P; Bluethmann H
J Inflamm; 1995-1996; 47(4):180-9. PubMed ID: 9144075
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation.
Wicovsky A; Henkler F; Salzmann S; Scheurich P; Kneitz C; Wajant H
Oncogene; 2009 Apr; 28(15):1769-81. PubMed ID: 19287455
[TBL] [Abstract][Full Text] [Related]
16. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development.
Arnott CH; Scott KA; Moore RJ; Robinson SC; Thompson RG; Balkwill FR
Oncogene; 2004 Mar; 23(10):1902-10. PubMed ID: 14661063
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte macrophage-colony stimulating factor and interleukin-3 increase expression of type II tumour necrosis factor receptor, increasing susceptibility to tumour necrosis factor-induced apoptosis. Control of leukaemia cell life/death switching.
Rae C; MacEwan DJ
Cell Death Differ; 2004 Dec; 11 Suppl 2():S162-71. PubMed ID: 15459750
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models.
Shibata H; Yoshioka Y; Ohkawa A; Abe Y; Nomura T; Mukai Y; Nakagawa S; Taniai M; Ohta T; Mayumi T; Kamada H; Tsunoda S; Tsutsumi Y
Cytokine; 2008 Nov; 44(2):229-33. PubMed ID: 18815054
[TBL] [Abstract][Full Text] [Related]
19. Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), in murine toxoplasmosis.
Deckert-Schlüter M; Bluethmann H; Rang A; Hof H; Schlüter D
J Immunol; 1998 Apr; 160(7):3427-36. PubMed ID: 9531303
[TBL] [Abstract][Full Text] [Related]
20. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.
Shibata H; Yoshioka Y; Ohkawa A; Minowa K; Mukai Y; Abe Y; Taniai M; Nomura T; Kayamuro H; Nabeshi H; Sugita T; Imai S; Nagano K; Yoshikawa T; Fujita T; Nakagawa S; Yamamoto A; Ohta T; Hayakawa T; Mayumi T; Vandenabeele P; Aggarwal BB; Nakamura T; Yamagata Y; Tsunoda S; Kamada H; Tsutsumi Y
J Biol Chem; 2008 Jan; 283(2):998-1007. PubMed ID: 18003610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
